BioDelivery Sciences International Inc. (NASDAQ:BDSI) was down 5.3% during trading on Monday . The company traded as low as $2.48 and last traded at $2.48, with a volume of 382,238 shares changing hands. The stock had previously closed at $2.62.

A number of equities research analysts recently commented on BDSI shares. FBR & Co reiterated a “positive” rating and set a $12.00 price target on shares of BioDelivery Sciences International in a report on Tuesday, March 29th. Zacks Investment Research lowered shares of BioDelivery Sciences International from a “buy” rating to a “hold” rating in a report on Tuesday, July 12th. Roth Capital restated a “buy” rating on shares of BioDelivery Sciences International in a report on Monday, March 28th. Cantor Fitzgerald lowered shares of BioDelivery Sciences International from a “buy” rating to a “hold” rating and decreased their price objective for the stock from $9.00 to $5.00 in a report on Wednesday, May 11th. Finally, Janney Montgomery Scott restated a “hold” rating and issued a $4.00 price objective on shares of BioDelivery Sciences International in a report on Tuesday, July 12th. Two analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $8.25.

The company’s market cap is $125.95 million. The stock’s 50 day moving average price is $2.46 and its 200 day moving average price is $3.16.

BioDelivery Sciences International (NASDAQ:BDSI) last released its quarterly earnings data on Tuesday, May 10th. The specialty pharmaceutical company reported ($0.36) earnings per share for the quarter, missing the consensus estimate of ($0.35) by $0.01. The company earned $3 million during the quarter, compared to analysts’ expectations of $2.96 million. BioDelivery Sciences International’s quarterly revenue was down 77.1% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.16) EPS. On average, analysts forecast that BioDelivery Sciences International Inc. will post ($1.19) earnings per share for the current year.

A number of institutional investors have recently made changes to their positions in the company. Sei Investments Co. increased its position in shares of BioDelivery Sciences International by 240.1% in the fourth quarter. Sei Investments Co. now owns 330,789 shares of the specialty pharmaceutical company’s stock worth $1,584,000 after buying an additional 233,519 shares in the last quarter. 1492 Capital Management LLC increased its position in shares of BioDelivery Sciences International by 8.3% in the fourth quarter. 1492 Capital Management LLC now owns 538,538 shares of the specialty pharmaceutical company’s stock worth $2,580,000 after buying an additional 41,069 shares in the last quarter. Bank of Montreal Can increased its position in shares of BioDelivery Sciences International by 3.6% in the fourth quarter. Bank of Montreal Can now owns 829,056 shares of the specialty pharmaceutical company’s stock worth $3,971,000 after buying an additional 28,838 shares in the last quarter. Turner Investments L.P. increased its position in shares of BioDelivery Sciences International by 55.4% in the fourth quarter. Turner Investments L.P. now owns 900,830 shares of the specialty pharmaceutical company’s stock worth $4,315,000 after buying an additional 321,290 shares in the last quarter. Finally, Russell Frank Co increased its position in shares of BioDelivery Sciences International by 57.5% in the fourth quarter. Russell Frank Co now owns 1,080,051 shares of the specialty pharmaceutical company’s stock worth $5,151,000 after buying an additional 394,272 shares in the last quarter.

BioDelivery Sciences International, Inc is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.